Advertisement

Lung

pp 1–8 | Cite as

Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis

  • Charlotte Berlier
  • Esther I. Schwarz
  • Stéphanie Saxer
  • Mona Lichtblau
  • Silvia UlrichEmail author
Pulmonary Hypertension
  • 117 Downloads

Abstract

Background

Patients with pulmonary arterial hypertension (PAH) and distal chronic thromboembolic pulmonary hypertension (CTEPH) who still reveal risk factors of worse prognosis on double combination therapy may benefit from add-on therapy with the novel oral selective prostacyclin receptor agonist selexipag.

Methods

We reviewed all patients with PAH/distal CTEPH in the Zurich cohort who received selexipag as add-on to oral combination therapy and retrieved New York Heart Association (NYHA) functional class, 6-min walk distance (6MWD), NT-pro-BNP, quality of life questionnaires (CAMPHOR and EuroQoL), tricuspid pressure gradient (TPG) by echocardiography and cardiopulmonary exercise test parameters (power output and oxygen uptake).

Results

Twenty-three patients with PAH/CTEPH (20/3), 14 females, median (quartiles) age 56 (46; 66) years received an oral triple therapy containing selexipag at a median dose of 2000 (1600; 3100) mcg during 221 (113; 359) days. The following parameters were stabilized from baseline to last FU: 6MWD (440 (420; 490) to 464 (420; 526) m), NYHA class (three to two), NT-pro-BNP (326 (167; 1725) to 568 (135; 1856)  ng/l), TPG, power output, and oxygen uptake. Quality of life reflected by the CAMPHOR and EuroQoL improved.

Conclusions

Early initiation of triple oral combination therapy including selexipag in PAH/CTEPH with intermediate risk factor profile may help to stabilize functional class, exercise performance, and pulmonary hemodynamics in a real-life setting and potentially improves quality of life. Whether these beneficial effects can be truly attributed to the addition of selexipag should be addressed in future randomized controlled trials.

Keywords

Pulmonary hypertension Pulmonary arterial hypertension Vasodilator therapy Endothelin receptor antagonist Phosphodiesterase inhibitor Selexipag Chronic thromboembolic pulmonary hypertension 

Notes

Funding

The study was funded by grants for the Zurich PH cohort from the Zurich Lung.

Compliance with Ethical Standards

Conflict of interest

None of the authors declares any conflict of interest in relation to the present work. SU received grant money from the Swiss National Science Foundation, Zurich Lung, Actelion SA, Bayer SA, Orpha Swiss. SU; EIS, SS, ML and CB received travel support and lecture fees from Actelion SA, Bayer SA, MSD SA and Orpha Swiss.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This retrospective cohort study complied with the ethical laws in Switzerland and all patients have signed informed consent for the Zurich PH cohort study (KEK 2014-0214).

References

  1. 1.
    Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 37(1):67–119Google Scholar
  2. 2.
    Wilkens H, Konstantinides S, Lang I, Bunck AC, Gerges M, Gerhardt F et al (2016) Chronic thromboembolic pulmonary hypertension: recommendations of the Cologne Consensus Conference 2016. Dtsch Med Wochenschr 141(S01):S62–S69Google Scholar
  3. 3.
    Ulrich S, Fischler M, Speich R, Popov V, Maggiorini M (2006) Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 130(3):841–846CrossRefGoogle Scholar
  4. 4.
    Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R et al (2006) Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 28(4):808–815CrossRefGoogle Scholar
  5. 5.
    Cannon JE, Pepke-Zaba J (2013) Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs? Semin Respir Crit Care Med 34(5):620–626CrossRefGoogle Scholar
  6. 6.
    Voelkel NF, Cool C (2004) Pathology of pulmonary hypertension. Cardiol Clin 22(3):343–351CrossRefGoogle Scholar
  7. 7.
    Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV et al (2015) Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373(9):834–844CrossRefGoogle Scholar
  8. 8.
    Galie N, Muller K, Scalise AV, Grunig E (2015) PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 45(5):1314–1322CrossRefGoogle Scholar
  9. 9.
    Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369(9):809–818CrossRefGoogle Scholar
  10. 10.
    Bartenstein P, Saxer S, Appenzeller P, Lichtblau M, Schwarz EI, Ulrich S (2018) Risk factor profiles achieved with medical therapy in prevalent patients with pulmonary arterial and distal chronic thromboembolic pulmonary hypertension. Respiration 96(1):127–137CrossRefGoogle Scholar
  11. 11.
    Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Jais X et al (2016) Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 47(6):1727–1736CrossRefGoogle Scholar
  12. 12.
    Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330–340CrossRefGoogle Scholar
  13. 13.
    Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N et al (2012) Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40(4):874–880CrossRefGoogle Scholar
  14. 14.
    Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N et al (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522–2533CrossRefGoogle Scholar
  15. 15.
    Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galie N et al (2017) Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 50(2):1602493CrossRefGoogle Scholar
  16. 16.
    Mueller-Mottet S, Stricker H, Domenighetti G, Azzola A, Geiser T, Schwerzmann M et al (2015) Long-term data from the Swiss pulmonary hypertension registry. Respiration. 89(2):127–140CrossRefGoogle Scholar
  17. 17.
    Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D et al (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124(18):1973–1981CrossRefGoogle Scholar
  18. 18.
    Evangelista A, Flachskampf F, Lancellotti P, Badano L, Aguilar R, Monaghan M et al (2008) European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. Eur J Echocardiogr 9(4):438–448CrossRefGoogle Scholar
  19. 19.
    Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S et al (2017) A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 39(47):4175–4181CrossRefGoogle Scholar
  20. 20.
    Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G et al (2017) Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 50(2):1700889CrossRefGoogle Scholar
  21. 21.
    Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N et al (2017) Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 50(2):1700740CrossRefGoogle Scholar
  22. 22.
    Coghlan JG, Channick R, Chin K, Di Scala L, Galie N, Ghofrani HA et al (2018) Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs 18(1):37–47CrossRefGoogle Scholar
  23. 23.
    McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S et al (2013) Treatment goals of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D73–D81CrossRefGoogle Scholar
  24. 24.
    Deboeck G, Scoditti C, Huez S, Vachiery JL, Lamotte M, Sharples L et al (2012) Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J 40(6):1410–1419CrossRefGoogle Scholar
  25. 25.
    McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J (2006) The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 15(1):103–115CrossRefGoogle Scholar
  26. 26.
    Cima K, Twiss J, Speich R, McKenna SP, Grunig E, Kahler CM et al (2012) The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR). Health Qual Life Outcomes 10(1):110CrossRefGoogle Scholar
  27. 27.
    Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J et al (2008) The responsiveness and validity of the CAMPHOR utility index. Eur Respir J 32(6):1513–1519CrossRefGoogle Scholar
  28. 28.
    Brooks R (1996) EuroQol: the current state of play. Health Policy 37(1):53–72CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Charlotte Berlier
    • 1
  • Esther I. Schwarz
    • 1
  • Stéphanie Saxer
    • 1
  • Mona Lichtblau
    • 1
  • Silvia Ulrich
    • 1
    • 2
    Email author
  1. 1.Clinic of PulmonologyUniversity Hospital of ZurichZurichSwitzerland
  2. 2.Center for Integrative Human PhysiologyUniversity of ZurichZurichSwitzerland

Personalised recommendations